New Phase 3a data indicates that overweight or obese adults with comorbidities had greater improvements in weight loss, fasting plasma glucose (FPG), systolic blood pressure (SPB), and physical health scores with Saxenda (liraglutide [rDNA origin] injection; Novo Nordisk) compared to non-responders and those on placebo treatment. The results were presented at ENDO 2015, The Endocrine Society’s 97th Annual Meeting in San Diego, CA.

The SCALE Obesity and Pre-diabetes trial, a randomized, double-blind, placebo-controlled, multinational study sought to evaluate the safety and efficacy of Saxenda in 3,731 non-diabetic adults with obesity and non-diabetic overweight adults with comorbidities. Patients were randomized to receive Saxenda or placebo in combination with a reduced-calorie diet and increased physical activity and stratified to 56 weeks or 160 weeks of treatment based on pre-diabetes status at baseline screening.

RELATED: Pharmacologic Management of Obesity: Endocrine Society’s New Guidelines

Approximately 63% of adults in the Saxenda arm achieved a clinically meaningful body weight reduction of ≥5% (responders) vs. 27.1% with placebo (P<0.0001). A greater reduction in waist circumference was observed in the Saxenda group vs. non-responders (11cm vs. 3.3cm), along with a greater improvement in fasting plasma glucose, SBP, and physical health scores compared with placebo and non-responders.

Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese) or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).

For more information visit